Tessera Therapeutics
Paul Scott is an Associate Scientist at Tessera Therapeutics, with previous roles including Senior Research Associate. Prior experience includes positions at Voyager Therapeutics, Inc. as Associate Scientist II and Associate Scientist I, and a contract role at Ultragenyx Pharmaceutical Inc. in the Analytical Development sample characterization group. Prior to that, Paul worked as a Research Technician at Harvard Medical School, managing an InDrop single cell RNA sequencing platform, and completed a summer internship at Biogen specializing in gene expression studies. Educationally, Paul Scott holds a Bachelor of Arts in Chemistry with a focus on Biochemistry from Colby College, where research involved developing mass spectrometric methods for analyzing DNA lesions.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.